₦airaland Forum

‘The Greek Freak’ wants to go back to his Nigerian roots

Bucks star Giannis Antetokounmpo opens up about his African upbringing

Giannis Antetokounmpo says he is not just “The Greek Freak.” Gary Dineen/NBAE via Getty Images

BY MARC J. SPEARS@MARCJSPEARSESPN

March 5, 2019

“The Greek Freak” can’t wait to go learn more about his roots.

His roots in Lagos, Nigeria.

“Obviously, a lot of people don’t know where I’m from,” Milwaukee Bucks All-Star Giannis Antetokounmpo told The Undefeated. “A lot of people think my mom or my dad are from Greece, but no. Both of my parents are black. Both of my parents are Nigerian.”

Charles and Veronica Adetokunbo moved from Lagos to Greece in 1991 in hopes of a better future for themselves and their family after struggling to find employment. The Adetokunbos’ eldest son, Francis, was left behind in Lagos to be raised by his grandparents. Charles Adetokunbo worked as a handyman and wife Veronica as a baby sitter in their struggle to make ends meet for their family, which was the only black one in the area, according toThe New York Times. The Adetokunbos had four more sons, all born in Greece, including Giannis on Dec. 6, 1994. (Antetokounmpo became Giannis’ surname after it was spelled that way on his Greek passport instead of his birth name of Adetokunbo.)

Antetokounmpo grew up in Greek culture learning the language, going to school and eventually starting to play basketball at age 7. But when he was home with his family, he learned and lived the Nigerian way.

“I grew up in a Nigerian home,” Antetokounmpo said. “Obviously, I was born in Greece and went to school in Greece. But at the end of the day when I go home, there is no Greek culture. It’s straight-up Nigerian culture. It’s about discipline, it’s about respecting your elders, having morals.”

Veronica Adetokunbo spoke to her sons in the Nigerian language of Igbo, which is one of the four official Nigerian languages and is spoken by about 18 million people in Nigeria and Equatorial Guinea, according to several websites.

“I can understand it a little bit. I can count. It’s not like I’m fluent,” Antetokounmpo said of Igbo. “It’s not like I can go back home to Nigeria and they can understand what I am saying. It’s kind of funny.

“Both my parents are from Nigeria. But Nigeria is like 250 dialects, so my mom and my dad don’t speak the same language.”

Hall of Famer Hakeem Olajuwon, who is arguably the greatest international basketball player of all time and one of the greatest NBA players, also has a Nigerian connection with Antetokounmpo. Olajuwon told The Undefeated that he and Antetokounmpo are Yoruba.

“I know from his last name that we are from the same tribe, the Yoruba tribe. His last name, which in Yoruba is spelled Adetokunbo, means ‘the crown has returned from overseas,’ ” Olajuwon said.

With the Bucks owning the best record in the NBA, Antetokounmpo appears to be the front-runner for the 2019 NBA MVP award, competing against the likes of the Houston Rockets’ James Harden, the Oklahoma City Thunder’s Paul George and the Golden State Warriors’ Stephen Curry and Kevin Durant. Antetokounmpo is averaging 27.1 points, 12.6 rebounds and six assists and led the Eastern Conference in All-Star votes.

“I’m sure Nigerians are very proud of him, especially because of the way he has conducted himself and how he is dominating the league,” Olajuwon said. “He has accomplished a great deal in such a short period of time.”



Giannis Antetokounmpo visited South Africa as part of Basketball Without Borders in 2015.

JOE MURPHY/NBA VIA GETTY IMAGES

Antetokounmpo wasn’t projected to be a superstar when he was selected 15th overall in the first round of the 2013 NBA draft by the Bucks. But former Warriors center Festus Ezeli, also a native of Nigeria, believed Antetokounmpo would be special after seeing him score a game-high 22 points for Team Africa in the first Africa Game in Johannesburg, on Aug. 1, 2015. The exhibition was Antetokounmpo’s first trip to Africa.

“Oh, my God, he took over for Team Africa in South Africa,” Ezeli said. “We were talking about it on the bench, ‘This kid right here. …’ I was thinking, ‘Yo, this kid is really special.’ Just the ease of how he did things and the way he was getting to the cup, the athleticism was there. And in a friendly game in Africa, the competitiveness and edge were there.”

Olajuwon also spent time with Antetokounmpo on the trip and said he enjoyed meeting his family.

“It is always good to trace back your roots,” Olajuwon said.

Antetokounmpo hasn’t traced his roots in person yet but says he hopes to visit Nigeria either this summer or next summer. He said he nearly went to Nigeria last summer, but “my mom said, ‘No, don’t go, because everyone is going to be on top of you.’ ”

Sadly, his father died at the age of 54 after a heart attack in 2017.

“I want to see where my family comes from, where my mom was raised, see my family, see where my dad was raised. That is very important. I hope my kids can do the same thing for me,” Antetokounmpo said. “Obviously, I am going to have kids that are going to grow up in the U.S., but one day I hope they can go back [to Greece] and visit and see where I grew up, the playground I was playing.”

Antetokounmpo said he also got his Nigerian passport in 2015.

When asked why he acquired a Nigerian passport, Antetokounmpo answered, “It’s important. It’s part of who I am. Both of my parents are Nigerian. They wanted me to get it. I wanted to have it, so I got it.”

“The Greek Freak” said during the recent NBA All-Star Weekend that he loves his nickname and it’s “a part of who I am right now.” But he also told The Undefeated that he is much more than just “The Greek Freak” by strongly stating he is also a proud African.

“There are a lot of people that I see and I tell them that I am African. I am not just ‘The Greek Freak,’ ” Antetokounmpo said.

“It doesn’t matter what people may believe because of my nickname. There were a lot of times when I was in Greece where people said, ‘You’re not Greek. You’re Nigerian because you’re black.’ But then there have been a lot of times where it’s been the opposite, where people say, ‘You’re not African. You're Greek. You’re ‘The Greek Freak.’ ’ But I don’t really care about that. Deep down, I know who I am and where I am from. That’s all that matters to me.”

Marc J. Spears is the senior NBA writer for The Undefeated. He used to be able to dunk on you, but he hasn’t been able to in years and his knees still hurt.

https://theundefeated.com/features/bucks-giannis-antetokounmpo-greek-freak-wants-to-go-back-to-his-nigerian-roots/

.

crossfm:
If you like pay 50k,it will never erase the fact that you are currupt.I hope they don't fall for his scarm.

The Govs that are not 'corrupt' are not willing to pay then what's the point.

I think it's better to prosecute him after his term.

You will deeply regret it if you marry such a woman. That's a ticking time bomb.

Billic:
5days and running, no reasonable game done boom from this Thread.

Just this whatsapp grp for reliable odds

https:// chat.w hatsapp.c om/F 1Ha4qgNv6r 28m4tfk VdDw

Remove the spaces

Sept 28

.

Sept 27
.

Sept 27

@ Sissy3 dominique Seun Lalasticlala

From death's door to the all-clear: Is Michael proof that doctors have FINALLY found the secret weapon to beat cancer?*.


Michael English, from Surrey, was told to prepare for the end after 13-year battle*.He was first diagnosed with aggressive stage 3/4 prostate cancer back in 2005*.Doctors tried various treatments, but the stubborn cancer always returned*.Now, he's been given the all-clear after ten doses of controversial new treatment

ByJohn Naish for the Daily MailPublished:17:59 EDT, 27 August 2018|Updated:02:19 EDT, 28 August 2018

Miraculous: Michael English is living evidence that we may finally have discovered a powerful secret to beating cancer. Michael English is living evidence that we may finally have discovered a powerful secret to beating cancer. Astonishingly, this long-sought answer lies hidden inside our own bodies.

Michael, a 72-year-old retired electrical engineer from Surbiton in Surrey, was first diagnosed with advanced and aggressive stage 3/4 prostate cancer 13 years ago. Each time doctors tried the latest treatment on him, be it hormones, drugs, radiotherapy or chemotherapy, his tumour was beaten back until it had apparently disappeared. But four times since 2005 the cancer returned, as each time a few of his tumour cells managed to evade medicine’s best weapons. They did this by mutating their DNA — adopting a new genetic guise that was resistant to all the therapies that had been tried. Michael was allocated palliative care nurses, to make his seemingly inevitable death as painless as possible. Conventional medicine had waved the white flag. For millions of cancer patients and their families, this is a familiar and tragic story. But now the tables are being turned. For British scientists are discovering that the very thing that can make cancer cells so relentlessly lethal — their ability to mutate and evade our best treatments — may also be their Achilles heel.

Researchers are discovering that each time the cancer mutates its DNA, it creates a tell-tale biological fingerprint. What’s more, our own immune systems can be taught to recognise these fingerprints, and then to attack and destroy these enemies within, so that they never come back. This new avenue is called cancer immunotherapy. There are several types of immunotherapy treatments, which either help the immune system attack cancer directly or boost it more generally. Last year Michael was inducted into a medical trial of a new immunotherapy drug by Professor Johann de Bono, the head of clinical studies at the Institute of Cancer Research in London.

Not giving up: Michael was allocated palliative care nurses, to make his seemingly inevitable death as painless as possible. Conventional medicine had waved the white flag. This may have seemed beyond optimistic. Not only was Michael past last chances in terms of conventional therapy, his intestines had been left so ravaged by previous doses of radiotherapy to kill tumours there that his gut was perforated, causing him crippling stomach infections. He was so ill there was little point subjecting him to abdominal surgery to repair this. Indeed, Michael was so ill that after only ten intravenous doses of the experimental drug pembrolizumab (branded as Keytruda), administered once every three weeks, he was taken off the trial. To complete the therapy he should have received a further 29 doses.

Nevertheless, Professor de Bono’s team gave him MRI scans to check his progress — and found his tumour had disappeared. That was in April last year. Destroying the cancer rendered Michael strong enough to receive the stomach surgery he needed. He had another cancer scan last week and he’s still clear. ‘It is absolutely incredible,’ he says. Professor de Bono describes Michael’s result as ‘profound and spectacular’. What’s more, this science could be repeated in future for millions of patients, experts believe. What made Michael, despite his frailty, such a good candidate for the trial is the fact that his cancer had aggressively mutated its DNA several times to evade conventional treatment — making it a good test for pembrolizumab’s mutation-targeting powers.

Pain: Not only was Michael past last chances in terms of conventional therapy, his intestines had been left ravaged by previous doses of radiotherapy‘ Patients like Michael have a defect in a gene called CDK12, which controls how a cell can repair faults in its DNA,’ explains Professor de Bono. This defect causes one in ten cases of prostate cancer. When the gene goes awry, DNA faults run rampant, causing cells to turn cancerous and replicate. The gene also gives tumours a deadly advantage — they change their DNA so quickly that they evade being wiped out by conventional drugs. ‘However, this could be an Achilles heel, because it also causes an increase in jumbled-up DNA that the immune system can more easily recognise as a threat,’ adds Professor de Bono.

To target the cancer cells, first you have to stop them from evading detection by the immune system by ‘cloaking’ themselves in proteins that identify them as healthy tissues. A new class of drugs rolled out over the past seven years, called ‘checkpoint inhibitors’, which include pembrolizumab, ‘unmask’ the cancer cells by blocking their fake cloaks. Our immune cells can then identify them as dangerous and destroy them. The idea behind cancer immunotherapy is not new. Yet it’s taken more than a century to prove its worth.

New York surgeon William Coley first explored the theory of using a patient’s immune system to fight cancer in the 1890s, after hearing of a man who recovered unexpectedly from cancer following a serious skin infection. Mr Coley believed the infection provoked the patient’s immune system to attack anything that looked alien, including the cancer cells. He vaccinated ten other cancer patients with cocktails of bacteria and claimed that, in several cases, this spurred their immune systems to destroy tumours. But the medical establishment refused to believe his patients had even had cancer.

Instead, cancer surgeons backed the new — and then highly dangerous — radiation therapy as their best hope of a cancer cure-all (the precursor to what we now know as radiotherapy).Mr Coley’s ideas languished for a century until an immunologist, Charles Janeway of Yale University, challenged a longstanding basic assumption — that our immune defences work simply by recognising things that haven’t been in the body before and attacking them.

But if that were true, Dr Janeway wondered, how could we ever eat a new food without suffering an allergic response? In the late Eighties, he realised that we must have two systems operating: one for detecting alien substances in our bodies; and another that learns to recognise which aliens are threats and flags them for attack. The implications were revolutionary. If our immune system could learn in this way, then it may also be taught to destroy a another threat: cancer cells.

TEACHING IMMUNE SYSTEM TO ATTACK. But no one believed Dr Janeway. His idea was shunned until the early 2000s, when international scientists finally began to appreciate its potential. For this, others were awarded the Nobel Prize in 2011. The accolade should arguably have been Dr Janeway’s but he had died in 2003 of lymphoma. A similar fate befell Ralph Steinman, who discovered the key biological mechanism behind Dr Janeway’s ideas — a spiky-looking cell that switches on our immune systems by identifying dangerous invaders. Dr Steinman, an immunologist at Rockefeller University in New York, christened his discovery the dendritic cell. But when he revealed his theories about the cells’ curative potential at medical conferences in the early 2000s, he was considered outlandish.

Nevertheless, Dr Steinman worked doggedly on using the cells to create cancer-killing vaccines. His colleague, Antony Rosen, now a professor of medicine at Johns Hopkins University, recalls: ‘He was confident enough that it didn’t matter to him that nobody had seen it before and everybody rejected what he said’. Dr Steinman’s investigations involved extracting dendritic cells from a patient, exposing them in the lab to the patient’s cancer cells — ‘teaching’ them to recognise them as threats — then injecting the dendritic cells back into the patient's body in order to prime their immune system. Dr Steinman pursued his goal with deadly urgency. In 2007, with his work still at an early point, he was diagnosed with aggressive pancreatic cancer and told he had only months to live. He experimented on himself — trying three previously untested vaccines based on dendritic cells exposed to cells from his tumor.

NEXT BREAKTHROUGH MAY BE FOUND IN MILK. Could having chemotherapy for cancer be as easy as drinking a glass of milk? Scientists in the U.S. claim they have found a way to turn the toxic tumour treatment, mainly given as an injection into a vein in the arm, into something patients can drink instead. It could mean cancer patients, who often need to attend hospital every day for a week for chemotherapy, can consume their medicine at home from a glass. Patients would have a daily dose of milk chemo as they would with injections. The unlikely new form of therapy is based on the science behind how mothers pass on infection-fighting antibodies to their babies through breast milk. Normally, anything that passes through the stomach gets broken down by the acidic environment so it can be digested. This means many drugs — including most of those used for chemotherapy — cannot be swallowed, as digestion would destroy them before they had a chance to get into the bloodstream. But scientists at the University of Colorado believe they may be able to smuggle chemotherapy medicine through the stomach using milk. Antibodies in a mother’s breast milk do not get destroyed by the baby’s stomach acid, and pass unscathed into the baby’s bloodstream. Tiny particles, called exosomes, in the mother’s milk seem to protect the antibodies. They bind to receptors in the tissue lining the baby’s intestines once they have passed through the stomach. These receptors allow the antibodies to penetrate into the bloodstream and trigger a reaction by the immune system, so that it is primed to attack an invading organism in the future. Cow’s milk is similar enough to human milk that the exosomes in it bind with these receptors in humans. The Colorado team has been given funding by the U.S. National Institutes of Health to incorporate chemotherapy medicine into exosomes in cow’s milk. Scientists are experimenting with chemo drugs in a lab to see which ones are able to attach to the milk particles. A separate study in 2017 by scientists at the University of Louisville in Kentucky found mice given milk containing the chemotherapy drug paclitaxel (used to treat breast, ovarian and lung cancers) saw a 60 per cent reduction in the size of their lung tumours after taking it daily for a week. The mice suffered fewer of the side-effects seen with chemotherapy treatment — including severe nausea, exhaustion and hair loss. Since paclitaxel is a licensed drug and milk is readily available the treatment could be used in the next three to five years if research proves it is safe and effective.

Cancer Research UK’s head information nurse Martin Ledwick said: ‘Anything that makes the delivery of chemotherapy drugs easier for patients has to be a good thing. 'Some drugs can be given orally but many need to be through an intravenous drip.‘ More work needs to be done to see if these experiments work in humans. ‘But if they do, it could reduce the discomfort and other problems associated with having a drip.’-

PAT HAGAN. He survived four years longer than doctors predicted, though it is impossible to know if his discovery extended his life, or if was just chance. Dr Steinman was among the pioneering immunotherapy scientists awarded the Nobel Prize in 2011. The announcement came three days after his death. Since then, one dendritic cell-based vaccine, Provenge, has been shown to increase the survival of prostate cancer patients by about four months. It is approved for use in the US.

Meanwhile in Britain, pioneering immunotherapy researchers also suffered derision and disbelief. Professor Charles Swanton, now the chief clinician at Cancer Research UK, recalls how in 1995, he was planning to do a PhD in using dendritic cells as a therapy for cancer. ‘I was very strongly discouraged from going into this field,’ he says. ‘In the Nineties it was unclear how this research would have any practical value. Research funders were sceptical. 'Peter Johnson, a professor of medical oncology at Southampton General Hospital, has been working since 1998 to get the human immune system to attack cancers. ‘For a long time immunology was regarded as interesting, but did not deliver much,’ he says. ‘It was a difficult field, because sadly the clinical trials of vaccines were mostly unsuccessful.

'DRUGS THAT LEND A HELPING HAND'
All of this is changing, however, with the advent of checkpoint inhibitor drugs — and their ability to unmask cancer cells to our immune defence. With unabashed satisfaction, Professor Johnson describes as ‘striking’ the cure rates these drugs have achieved in melanoma and tumours such as cancers of the kidney and cervix. Checkpoint drug therapy works in clinical trials for between a quarter and a third of people with melanoma and lung cancer. Beyond this, though, is the hope that these therapies may defeat cancer’s ability to return again, after seemingly lying dormant for months or years. A third of patients with advanced melanoma who received the checkpoint-inhibitor drug nivolumab in a clinical trial at Boston’s Dana-Farber Cancer Institute are still alive five years later. Previously the average survival time for advanced melanoma patients was 11 months.

PROTECTION THAT MAY LAST A LIFETIME
Professor Johnson believes that the immune system, once alerted to tumour cells, not only kills them but continues to search for them — and anything which looks like them that may be a surviving mutant STRAIN. He explains: ‘If you can get the immune system to lock on to a cancer then, like a vaccination, the benefits may last for life. ’However, there is work to be done if cancer immunotherapy is finally to achieve its promise. The drug that saved Michael English’s life, pembrolizumab, helps only one in ten men with prostate cancer, says Professor de Bono. Last month he published a study in the journal Cell which indicates that it may only save men with defects in the CDK12 gene.

The huge challenge is to discover why the drug only works for certain genetic types of tumour, and how to make immunotherapy work for the other nine in ten men with prostate cancer. Professor Swanton, part of a British commercial collaboration of clinical experts, is pinning his hopes on developing a specific type of checkpoint inhibitor drug in the hope that it will be a ‘one-size-fits-all’ cure. This targets something that he calls a ‘truncal mutation’, the very first gene change that occurs in a cell before it turns cancerous. Professor Swanton believes this single DNA mutation must be common to all cancers — unlike subsequent DNA changes which may all differ. The team plans soon to start trials with lung cancer and melanoma patients to see if they can identify this single change and target it for attack by the patient’s own immune system. If it works, it could be an astonishing breakthrough. The collaboration’s name is well chosen to explain its mission: Achilles Therapeutics. Cancer could finally be brought to heel. Tumours had spread to Judy's liver. Now she's cancer-free

Fighting: Judy Perkins, 51, an engineer from Florida, also overcame aggressive cancer. Judy Perkins, 51, an engineer from Florida, amazed the world when her doctors revealed that her breast cancer, which had spread lethally to her liver, had been eradicated. Two years ago she had been given only three years to live. But then she was given an intricate — and expensive — new cancer therapy. 'I had given up fighting,’ Judy told reporters. After the treatment dissolved most of my tumours, I was able to go for a 40-mile hike.’ Judy is living proof of the promise of immunotherapy.

There is one massive problem: the expense. Judy’s treatment is estimated to have cost £400,000.U.S. doctors treated Judy with an advanced form of immunotherapy called CAR-T cell therapy. This genetically alters a patient’s T-cells — the ‘troops’ in the immune system — so that they recognise and attack specific proteins found on cancer cells. This treatment is already being used to treat a small number of patients with blood cancers such as leukemia. Doctors took tissue from Judy’s tumours and studied its DNA for mutations specific to her cancer and extracted immune cells that had invaded the tumour to try to kill it. After growing billions of these immune cells in the lab, the researchers screened them to find which would attack Judy’s mutated cancer cells.

The doctors reported in the journal Nature Medicine in June how they injected 80 billion of these immune cells into Judy’s body, along with the immunotherapy drug pembrolizumab. As it stands, this procedure is too expensive for the NHS. The drug rationing watchdog the National Institute for Health and Care Excellence is expected to reject Yescarta — the first CAR-T drug to be assessed — due to the high cost.

Professor David Cunningham, a consultant oncologist at the Royal Marsden in London, says: ‘Harvesting and modifying the patient’s T-cells can cost around £500,000 per patient. That is prohibitive.

'However, in June U.S. researchers announced that they may have discovered a cheaper way of creating CAR-T cancer-killing cells. Rather than taking immune cells out of each individual patient, the scientists, from the Universities of California and Minnesota, say they may be able to mass-produce cancer-destroying immune cells from human stem cells.

In the journal Cell Stem Cell, they reported that they can produce a ‘natural killer cell’ to identify and kill all tumors. Dan Kaufman, a professor of medicine at the University of California, San Diego, who led the study, said: ‘One batch of stem cell-derived natural killer cells can potentially be used to treat thousands of patients. ’Professor Kaufman says that the new drugs have already shown considerable curative promise in experiments in mice. Further trials will be needed before the worth of this approach is proven — so it is still, at best, several years before it is available to more patients. Even so, it is a tantalising hope.

http://www.dailymail.co.uk/health/article-6103647/Is-Michael-proof-doctors-FINALLY-secret-weapon-beat-cancer.html

justwise:
If you don't hear from them by this coming Friday then you can email them.

Thank you for your timely response kind sir.

What is their email address, sir? Thank you

ekpotek:
No. The tracking you displayed shows that your application has been received by UKVI. You need to exercise patience until a decision is made, typically within 15 days.

My processing started on 5th July. We are in August, kind sir. Is this normal?

Good afternoon @Justwise

I applied for a visiting visa and I did my biometrics on 5th July. Till now I am yet to get a response concerning my application.

My question is that:

Is it necessary or overdue that I should contact them due to the late turnaround time.

If yes, how do I go about it? I meant is it by mail or a visit to the Lagos centre or i may have to ring them. Thank you.

Grateful assist

By Max Winters For Mailonline


Arsenal's deal with BYD Auto was signed by someone acting as an employee
It seems the person who sanctioned the agreement doesn't worked for the firm
The suspected fraudster is currently being investigated by Shanghai police
Arsenal published a lengthy statement to announce the partnership in April
Arsenal have fallen victim to an embarrassing scam after it seems their deal with vehicle manufacturer BYD Auto was signed off by someone acting as an employee of the Chinese company.

The Gunners revealed in April that they had penned a deal with 'the world's best-selling electric vehicle manufacturer'.

However, just three months later it appears the employee of the Chinese company who sanctioned the agreement, in fact, didn't even work there.

Arsenal's BYD Auto deal was signed off by someone acting as an employee of the car company.


The suspected fraudster, Li Juan, has now been detained and is currently being investigated by Shanghai police.

Reports suggest Juan rented property in the Chinese city and tricked potential clients into believing he had opened a BYD branch there.

BYD - which stands for Build Your Dreams - designs, develops, manufactures and distributes cars, buses, commercial vehicles and rail stock.

It also provides buses to Transport for London and employs more than 220,000 employees across five continents.

Arsenal released an official statement on their website to announce the new partnership
In a statement published after signing the deal, Arsenal insisted the partnership 'came to fruition following our successful pre-season tour to Shanghai and Beijing in 2017'.

It was accompanied by a picture of Gunners stars Granit Xhaka, Laurent Koscielny and Shkodran Mustafi holding a shirt, upon which 'BYD 1' was printed.

As part of the package, BYD would receive 'pitchside LED signage' and 'branding on dugout seats' at the Emirates Stadium. It also had access to Arsenal Legends for special promotional events in China.

Reports suggest Li Juan rented property in Shanghai in a bid to trick potential clients
BYD issued a statement to the Hong Kong stock exchange last week in which they claimed foul play.

It said: 'Recently, BYD Company Limited noticed that some media published or reproduced false reports about the Company, which involved misinterpretation of the Statement on Conducting Related Businesses by Li Juan and Other Related Persons through Illegal Use of the Name of BYD released by the Company on 12 July 2018 and distortion of facts.

'Such reports caused the question to the Company from the public and negative impact on the Company, to some extent.

'Li Juan was suspected of committing a crime due to faking the identity of staff of BYD and using the forged seal to sign contracts, which BYD has reported to the police.

'The police is getting involved in the investigation and Li Juan currently has been taken for enforcement actions by the police.'



Source: https://www.google.com.ng/amp/www.dailymail.co.uk/sport/football/article-5960355/amp/Arsenal-fall-victim-embarrassing-scam-BYD-Auto-partnership.html

xxxzotique:
No periods for over 7 months

go to SCOAN at Ikotun

CrownGamers:
Bro can this game be played online with and against other players as per e-sports.....i would love to play it with and against other good players and I found a nigerian e-sports website where gamers of all (pc,ps4,xbox)consoles/pc come together to play tournaments and head to head challenges .... its dope as hell

I would love to play this game there bro....please tell me about it

Yes. its an online game. Download and see

Hello house,
Please what is the price of PKC per tonne, also where is the best place to source at reasonable prices. Thanks

PCGamesLab:
this is cool.

very cool and fun. I am on Server 80 should in case you join. SWS Alliance

The hottest free to play multiplayer war game of 2017 is here! Become an admiral of invincible navy fleets in the best 3D interactive strategy game of naval warfare. Build your naval base and lead your powerful fleet into countless epic sea battles. Grow stronger by forging alliances with friends and build an empire together. Wage war against pirates, sea monsters, and players from around the globe! Fighting for world domination now in a mobile MMO!


Please who knows a working cheat

How do we get there?



Just raising our hopes for nothing